FY2026 Earnings Estimate for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Ardelyx in a research note issued to investors on Friday, February 20th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of $0.18 per share for the year, up from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. The firm had revenue of $125.22 million for the quarter, compared to analysts’ expectations of $118.04 million. During the same period in the previous year, the firm posted $0.02 EPS. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year.

A number of other equities research analysts also recently commented on ARDX. Wedbush increased their price objective on shares of Ardelyx from $16.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Ardelyx in a report on Tuesday, January 27th. Piper Sandler raised shares of Ardelyx from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $10.00 to $16.00 in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ardelyx in a report on Wednesday, January 21st. Finally, TD Cowen restated a “buy” rating on shares of Ardelyx in a research note on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.09.

Ardelyx Trading Down 15.0%

Shares of ARDX stock opened at $5.73 on Monday. Ardelyx has a 1-year low of $3.21 and a 1-year high of $8.40. The company has a 50-day moving average of $6.77 and a two-hundred day moving average of $6.12. The firm has a market cap of $1.41 billion, a PE ratio of -22.92 and a beta of 0.57. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.31 and a quick ratio of 4.11.

Insider Transactions at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 50,000 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.98, for a total value of $349,000.00. Following the sale, the insider directly owned 361,563 shares of the company’s stock, valued at $2,523,709.74. This trade represents a 12.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ardelyx

Large investors have recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV increased its holdings in shares of Ardelyx by 4.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 1,722 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ardelyx by 26.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,807 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,491 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its position in Ardelyx by 0.7% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 347,609 shares of the biopharmaceutical company’s stock worth $2,027,000 after purchasing an additional 2,532 shares in the last quarter. Merit Financial Group LLC raised its position in Ardelyx by 12.0% during the third quarter. Merit Financial Group LLC now owns 23,680 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 2,537 shares during the period. Finally, Brighton Jones LLC boosted its stake in shares of Ardelyx by 25.1% during the 3rd quarter. Brighton Jones LLC now owns 12,701 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 2,550 shares during the period. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Strong commercial growth — IBSRELA revenue grew 73% in 2025 to $274.2M and total revenues reached $407.3M, demonstrating meaningful top-line momentum that supports future cash flow potential. Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue beat — Q4 revenue of $125.2M topped analyst estimates (~$118M), showing continued commercial execution even as EPS missed. MarketBeat Q4 results summary
• Positive Sentiment: Bullish analyst support — BTIG reaffirmed a buy rating and set a $17 price target, and at least one firm reportedly raised its target sharply (~+80%), showing divergent analyst views and potential upside if sentiment improves. Benzinga note on BTIG rating
• Neutral Sentiment: Earnings call and disclosures — the full Q4 earnings call transcript is available; management reiterated the XPHOZAH access strategy and said the company is well-capitalized to pursue growth and development programs. Investors will parse the call for guidance on margins and R&D spend. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Data noise on short interest — several data feeds reported large short-interest “increases” but with zero shares and NaN changes, indicating erroneous/unclear short-interest reporting rather than a meaningful squeeze or piling on. Investors should treat those items cautiously.
• Negative Sentiment: EPS miss and margin concerns — Ardelyx reported EPS of ($0.01) vs. consensus $0.02, and commentary showed heavy operational spend that clouds near-term profitability; that miss is the primary near-term driver of selling pressure. Zacks Q4 EPS coverage
• Negative Sentiment: Mixed investor reaction to outlook — post-earnings commentary and coverage highlighted concerns about the IBSRELA outlook and high operating expenses, which prompted the stock decline despite strong sales numbers. Seeking Alpha: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.